EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Terumo's enterprise value is $25,605 Mil.
Terumo's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $1,453 Mil. Therefore, Terumo's EV-to-EBITDA for today is 17.62.
The historical rank and industry rank for Terumo's EV-to-EBITDA or its related term are showing as below:
TRUMY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.37 Med: 19.14 Max: 31.18
Current: 17.63
During the past 13 years, the highest EV-to-EBITDA of Terumo was 31.18. The lowest was 13.37. And the median was 19.14.
TRUMY's EV-to-EBITDA is ranked worse than 60.94% of 489
companies
in the Medical Devices & Instruments industry
Industry Median: 14.89
vs TRUMY: 17.63
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Terumo's stock price is $17.05.
Terumo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.467. Therefore, Terumo's PE Ratio for today is 36.51.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Terumo EV-to-EBITDA Historical Data
The historical data trend for Terumo's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Terumo's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Terumo EV-to-EBITDA Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Terumo's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Terumo's EV-to-EBITDA falls into.
Terumo's current Enterprise Value is $25,605 Mil.
Terumo's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,453 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Terumo (OTCPK:TRUMY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Terumo's share price for today is $17.05.
Terumo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.467.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Terumo's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRUMY has been successfully added to your 